OXiGENE Announces Fourth Quarter and Fiscal 2009 Earnings Conference Call and Webcast

SOUTH SAN FRANCISCO, Calif., Feb. 19, 2010 (GLOBE NEWSWIRE) -- OXiGENE, Inc.
(Nasdaq:OXGN) (Stockholm:OXGN), a clinical-stage, biopharmaceutical company
developing novel therapeutics to treat cancer and eye diseases, will report
fourth quarter and fiscal year-end 2009 results, along with guidance for 2010,
on Thursday, February 25, 2010 . A conference call and webcast hosted by
OXiGENE management will begin at 4:30 pm EST (1:30 p.m. PST). 

To listen to a live or an archived version of the audio webcast, please log on
to the Company's website, www.oxigene.com. Under the "Investors" tab, select
the link to "Events & Presentations." 

OXiGENE's earnings conference call can also be heard live by dialing (888)
841-3431 in the United States and Canada, and +1 (678) 809-1060 for
international callers, five minutes prior to the beginning of the call. A
replay will be available starting at 7:30 p.m. EST, (4:30 p.m. PST) on February
25, 2010 and ending at midnight EST (9:00 p.m. PST) on Wednesday, March 10,
2009. To access the replay, please dial (800) 642-1687 if calling from the
United States or Canada, or +1 (706) 645-9291 from international locations. 
Please refer to replay pass code 58560383. 

About OXiGENE

OXiGENE is a clinical-stage biopharmaceutical company developing novel
therapeutics to treat cancer and eye diseases. The company's major focus is
developing vascular disrupting agents (VDAs) that selectively disrupt abnormal
blood vessels associated with solid tumor progression and visual impairment.
OXiGENE is dedicated to leveraging its intellectual property and therapeutic
development expertise to bring life-extending and life-enhancing medicines to
patients. 

The OXiGENE, Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=4969 

CONTACT:  OXiGENE
          Investor and Media Contact:
          Investor Relations
          Michelle Edwards
          650-635-7006
          medwards@oxigene.com